Steven Gillis has an estimated net worth of $188 Million. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., PHASERX, INC., Neumora Therapeutics, Inc., Erasca, Inc., Pulmatrix, Inc., Verve Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Prime Medicine, Inc., Boundless Bio, Inc., Rapport Therapeutics, Inc., Metsera, Inc., Maze Therapeutics, Inc., Lyell Immunopharma, Inc., Seaport Therapeutics, Inc., DA32 Life Science Tech Acquisition Corp., VBI VACCINES INC., Trubion Pharmaceuticals, Inc, VBI Vaccines Inc/BC, bluebird bio, Inc., Codiak BioSciences, Inc., Homology Medicines, Inc., CORIXA CORP, and TAKEDA PHARMACEUTICAL CO LTD.

2023 was Steven Gillis's most active year for acquiring shares with 31 total transactions. Steven Gillis's most active month to acquire stocks was the month of May. 2005 was Steven Gillis's most active year for disposing of shares, totalling 22 transactions. Steven Gillis's most active month to dispose stocks was the month of June. 2025 saw Steven Gillis paying a total of $54,999,963.00 for 30,698,853 shares, this is the most they've acquired in one year. In 2014 Steven Gillis cashed out on 752,477 shares for a total of $9,305,060.48, their largest year based on trade value.